KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Profit After Tax (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Profit After Tax data on record, last reported at $208.5 million in Q4 2025.

  • For Q4 2025, Profit After Tax rose 9.07% year-over-year to $208.5 million; the TTM value through Dec 2025 reached -$351.1 million, down 162.65%, while the annual FY2025 figure was -$355.5 million, 163.46% down from the prior year.
  • Profit After Tax reached $208.5 million in Q4 2025 per JAZZ's latest filing, down from $251.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $251.4 million in Q3 2025 and bottomed at -$718.5 million in Q2 2025.
  • Average Profit After Tax over 5 years is $3.7 million, with a median of $52.0 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: plummeted 643.82% in 2022, then surged 4114.94% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$32.4 million in 2021, then tumbled by 643.82% to -$240.7 million in 2022, then soared by 139.11% to $94.2 million in 2023, then surged by 103.0% to $191.1 million in 2024, then increased by 9.07% to $208.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were $208.5 million in Q4 2025, $251.4 million in Q3 2025, and -$718.5 million in Q2 2025.